Core Insights - Alkermes (ALKS) is expected to report quarterly earnings of $0.43 per share, a decline of 58.7% year-over-year, with revenues forecasted at $379.96 million, reflecting an 11.6% decrease compared to the same period last year [1] Earnings Estimates - The consensus EPS estimate has been revised down by 152.2% over the last 30 days, indicating a significant reevaluation by analysts [2] - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock performance [3] Revenue Projections - Analysts predict 'Revenues- Product sales, net' to be $310.64 million, indicating a 1% increase from the prior-year quarter [5] - 'Revenues- Manufacturing and Royalty revenues' are expected to reach $71.23 million, reflecting a 41.7% decrease from the year-ago quarter [5] - 'Revenues- Proprietary Sales- LYBALVI' is estimated at $93.91 million, suggesting a 22% year-over-year increase [6] - 'Revenues- Manufacturing and Royalty Revenues- Long-acting INVEGA products' are projected at $27.82 million, indicating a 23.8% decrease from the prior-year quarter [6] - 'Revenues- Manufacturing and Royalty Revenues- VUMERITY' is forecasted to be $34.83 million, reflecting a 0.4% decrease year-over-year [7] - 'Revenues- Proprietary Sales- ARISTADA' is estimated at $93.77 million, indicating a 3% decrease from the prior-year quarter [7] - 'Revenues- Proprietary Sales- VIVITROL' is expected to be $122.43 million, reflecting an 8.7% decrease from the prior-year quarter [8] Stock Performance - Alkermes shares have shown a return of -2.8% over the past month, compared to a -1% change in the Zacks S&P 500 composite, with a Zacks Rank of 3 (Hold), suggesting that ALKS is expected to mirror overall market performance in the near future [8]